Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Nucrogene Inc
483
•Nucrogene Inc•October 9, 2024

FDA 483 - Nucrogene Inc - October 09, 2024

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Record Details

Nucrogene Inc, a drug manufacturer in Branchburg, NJ, was cited for significant deficiencies during an FDA inspection. The firm failed to follow its stability testing program, lacked appropriate controls for computer systems including audit trail reviews, and did not complete equipment cleaning validation for tablet presses. Additionally, annual product reviews were not conducted as required.

Company
Nucrogene Inc
Inspection Date
October 9, 2024
Product Type
Drugs
Office
New Jersey District Office
People
  • Alisha B. Patel
  • Victoria Spivak (Pharmacist | Consumer Safety Officer)
Open in Dashboard

ID · 482e5d3d-0a53-4ba9-9cb2-50047cfc6a2a

footer
Global Key Solutions
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026, Global Key Solutions All rights reserved.